Epidemiological modelling (including economic modelling) and its role in preventive drug therapy

被引:11
作者
Liew, D [1 ]
McNeil, JJ [1 ]
Peeters, A [1 ]
Lim, SS [1 ]
Vos, T [1 ]
机构
[1] Monash Univ, Alfred Hosp, Sch Med, Dept Epidemiol & Prevent Med,Epidemiol Modelling, Melbourne, Vic 3004, Australia
关键词
D O I
10.5694/j.1326-5377.2002.tb04839.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In contrast to curative therapies, preventive therapies are administered to largely healthy individuals over long periods. The risk-benefit and cost-benefit ratios are more likely to be unfavourable, making treatment decisions difficult. Drug trials provide insufficient information for treatment decisions, as they are conducted on highly selected populations over short durations, estimate only relative benefits of treatment and offer little information on risks and costs. Epidemiological modelling is a method of combining evidence from observational epidemiology and clinical trials to assist in clinical and health policy decision-making. It can estimate absolute benefits, risks and costs of long-term preventive strategies, and thus allow their precise targeting to individuals for whom they are safest and most cost-effective. Epidemiological modelling also allows explicit information about risks and benefits of therapy to be presented to patients, facilitating informed decision-making.
引用
收藏
页码:364 / 367
页数:4
相关论文
共 15 条
[1]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[2]   Cost-effectiveness of Pravastatin in secondary prevention of coronary artery disease [J].
Ashraf, T ;
Hay, JW ;
Pitt, B ;
Wittels, E ;
Crouse, J ;
Davidson, M ;
Furberg, CD ;
Radican, L .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (04) :409-414
[3]   The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin [J].
Caro, J ;
Klittich, W ;
McGuire, A ;
Ford, J ;
Norrie, J ;
Pettitt, D ;
McMurray, J ;
Shepherd, J .
BRITISH MEDICAL JOURNAL, 1997, 315 (7122) :1577-1582
[4]   Primary and subsequent coronary risk appraisal: New results from The Framingham Study [J].
D'Agostino, RB ;
Russell, MW ;
Huse, DM ;
Ellison, RC ;
Silbershatz, H ;
Wilson, PWF ;
Hartz, SC .
AMERICAN HEART JOURNAL, 2000, 139 (02) :272-281
[5]   HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[6]   Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations - A statement for healthcare professionals from the American Heart Association and the American College of Cardiology [J].
Grundy, SM ;
Pasternak, R ;
Greenland, P ;
Smith, S ;
Fuster, V .
CIRCULATION, 1999, 100 (13) :1481-1492
[7]  
HEADY JA, 1980, LANCET, V2, P379
[8]   Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease [J].
Johannesson, M ;
Jonsson, B ;
Kjekshus, J ;
Olsson, AG ;
Pedersen, TR ;
Wedel, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (05) :332-336
[9]   Cost-effectiveness of prescribing statins according to Pharmaceutical Benefits Scheme criteria [J].
Lim, SS ;
Vos, T ;
Peeters, A ;
Liew, D ;
McNeil, JJ .
MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 (09) :459-+
[10]   Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials [J].
Pignone, M ;
Phillips, C ;
Mulrow, C .
BRITISH MEDICAL JOURNAL, 2000, 321 (7267) :983-986